Overview

Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Status:
Completed
Trial end date:
2017-09-12
Target enrollment:
0
Participant gender:
All
Summary
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pearl Therapeutics, Inc.
Treatments:
Budesonide
Formoterol Fumarate
Glycopyrrolate
Criteria
Inclusion Criteria:

Given their signed written informed consent to participate. Must have agreed to participate
in and complete the lead-in Study PT010006.(NCT02497001)

Exclusion Criteria:

Severe osteoporosis Unable to achieve an acceptable DEXA scan Inability to achieve pupil
dilation to at least 6 mm Subjects with an implanted artificial intraocular lens or are
scheduled to undergo cataract surgery